TORONTO, March 21, 2017 /PRNewswire/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] reported today the results of its 2017 annual general and special meeting of shareholders held on March 21, 2017.

All directors nominated, as listed in the Company's management information circular dated February 15, 2017 (the "Information Circular"), were re-elected as members of the board as follows:



    Director   Votes For(*)           % For        Withheld Votes(*)        %
    --------    -----------           -----        ----------------        ---

     Michael
     Cloutier              55,014,419       99.70%                165,368      0.30%
     --------              ----------        -----                 -------       ----

     Robert
     S.
     Pollock               55,006,380       99.69%                173,407      0.31%
     -------               ----------        -----                 -------       ----

     Timothy
     G.
     Sorensen              54,994,235       99.66%                185,552      0.34%
     --------              ----------        -----                 -------       ----

     David
     D.
     Guebert               55,018,949       99.71%                160,838      0.29%
     -------               ----------        -----                 -------       ----

     Theresa
     Firestone             55,018,300       99.71%                161,487      0.29%
     ---------             ----------        -----                 -------       ----

     Barry
     Fishman               55,014,516       99.70%                165,271      0.30%
     -------               ----------        -----                 -------       ----

     Robert
     Bloch                 55,001,680       99.68%                178,107      0.32%
     ------                ----------        -----                 -------       ----

((*)) Reflects votes represented by proxy

In addition, shareholders of the Company approved:


    --  the appointment of MNP LLP, Chartered Accountants, as the auditor of
        Merus to hold office until the next annual meeting of shareholders,
    --  the amendments to the Company's stock option plan announced on March 13,
        2017,
    --  the continuation of the Company's stock option plan for an additional
        three year term, and
    --  the amendments to the Company's articles, as described in the
        Information Circular, by special resolution.

About Merus Labs

Merus Labs is a specialty pharmaceutical company focused on acquiring and optimizing established and growth products. The Company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.

SOURCE Merus Labs Inc.